245 related articles for article (PubMed ID: 27863179)
1. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.
Svensson EM; Dosne AG; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):682-691. PubMed ID: 27863179
[TBL] [Abstract][Full Text] [Related]
2. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
[TBL] [Abstract][Full Text] [Related]
3. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
5. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
6. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Svensson EM; Dooley KE; Karlsson MO
Antimicrob Agents Chemother; 2014 Nov; 58(11):6406-12. PubMed ID: 25114140
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
Svensson EM; Murray S; Karlsson MO; Dooley KE
J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
[TBL] [Abstract][Full Text] [Related]
9. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
10. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
Tanneau L; Karlsson MO; Diacon AH; Shenje J; De Los Rios J; Wiesner L; Upton CM; Dooley KE; Maartens G; Svensson EM
Clin Pharmacokinet; 2022 Aug; 61(8):1177-1185. PubMed ID: 35668346
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
van Heeswijk RP; Dannemann B; Hoetelmans RM
J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
Nagabushan H; Roopadevi HS
J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
[TBL] [Abstract][Full Text] [Related]
16. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.
Tanneau L; Svensson EM; Rossenu S; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
Zou J; Chen S; Rao W; Fu L; Zhang J; Liao Y; Zhang Y; Lv N; Deng G; Yang S; Lin L; Li L; Liu S; Qu J
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081122. PubMed ID: 36106884
[TBL] [Abstract][Full Text] [Related]
18. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Kunkel A; Cobelens FG; Cohen T
PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
Gras J
Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
[TBL] [Abstract][Full Text] [Related]
20. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
